[TimAlerts] The impact of the FDA's decision on the rare disease space: $SRPT PTCT $ALXN $BMRN IONS RARE (and others..) pic.twitter.com/CpOAQCbmmY

[TimAlerts] Presumably the $SRPT and $BMRN drugs will be approved by NICE too and then the actual PTCT sales will be small because the other companies' drugs are better

[TimAlerts] Adam Feuerstein @adamfeuerstein $BMRN Post-call, I think regulatory & commercial risk for pegvaliase is higher. Neurcog trend went AGAINST drug. Wasn’t clear from PR.

[TimChallenge] **$BMRN sorry typo abvoe